Quel est le prix pour EQRx, Inc. (EQRX)

Le prix pour EQRx, Inc. (EQRX) est $2.34

Quelle est la capitalisation boursière pour EQRx, Inc. (EQRX)

La capitalisation boursière pour EQRx, Inc. (EQRX) est $728.90M

EQRx, Inc. (EQRX) BPA

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Année	EPS	Changez
Pas assez de données pour les dates fournies.

Année

EPS

Changez

Pas assez de données pour les dates fournies.

Entreprise	EPS	Différence d’EPS	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$-5.29	-	AU
Moderna, Inc. MRNA.US	$-7.98	-	US
Lonza Group AG LONN.SW	-	-	CH

Entreprise

EPS

Différence d’EPS

Pays